Northwest Biotherapeutics reported -21209000 in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agenus AGEN:US $ -44.56M 9.1M
Applied Genetic Technologies AGTC:US $ -17.72M 4.14M
AstraZeneca AZN:LN 44.27B 22.58B
Bristol Myers Squibb BMY:US $ 2590M 37M
Celldex Therapeutics CLDX:US $ -36.4M 13.14M
Cti Biopharma CTIC:US $ -18.88M 16.22M
Cytori Therapeutics CYTX:US $ -5120000 1.19M
Cytrx CYTR:US -1294610 7.73M
Eisai 4523:JP Y 7434M 28237M
Genocea Biosciences GNCA:US $ -15.77M 2.36M
Infinity Pharmaceuticals INFI:US $ -12.02M 0.39M
Merk MRK:US $ 4927M 642M
Mirati Therapeutics MRTX:US $ -177.2M 7.01M
Northwest Biotherapeutics NWBO:US -21209000 9.33M
Pfizer PFE:US $ 12102M 2229M